The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury - a Feasibility Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
This study aims to investigate shorter vs. standard filter lifespans in critically ill patients receiving continuous renal replacement therapy (CRRT) for acute kidney injury (AKI). The aim of this trial is to reliably implement,scheduled filter changes and to investigate whether shorter filter lifetime is associated with a lower incidence in rate of new infections.
详细描述
Own data of patients under standard care indicated that a longer filter lifetime in CRRT is associated with an increased rate of new infections.
The aim of this study is to demonstrate that a protocolized filter-change strategy can be reliably implemented in critically ill patients and a high protocol adherence can be achieved.
The secondary aim is to investigate whether a shorter filter-change strategy is be associated with a lower incidence of newly acquired infections.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult ≥ 18 years
- •Critically ill patients with severe AKI consistent with KDIGO stage 3 and an absolute indication for CRRT
- •Written consent form from the patient or legal representative or authorized representative or emergency inclusion
排除标准
- •End-stage kidney disease or chronic dialysis dependence
- •Chronic kidney disease with eGFR<20ml/min/1.73 m²
- •Prior kidney transplant
- •Prior renal replacement therapy during the index admission before randomization
- •Glomerulonephritis, interstitial nephritis, vasculitis
- •Patients on immunosuppression (above the cushing threshold)
- •Patients with chronic inflammatory diseases (e.g. arthritis, HIV with a CD4 count of < 0.05 x 10E/l)
- •Do-not resuscitate order
- •Persons with any kind of dependency on the investigator or employed by the sponsor
- •Patients participating in an interventional study involving measures to influence the immune system